• In May 2026, Wave Life Sciences reported updated RestorAATion-2 data showing its investigational RNA editor WVE-006 reduced harmful Z-AAT protein and restored protective M-AAT to levels comparable with lower-risk Pi*MZ individuals, while maintaining a favorable safety profile and convenient subcutaneous dosing.
• Crucially, WVE-006 appeared to re-establish the body’s ability to rapidly boost AAT during acute inflammatory episodes, a key functional behavior that current augmentation therapy does not replicate.
• We’ll now examine how this restoration of an MZ-like phenotype with sustained monthly dosing could influence Wave Life Sciences’ broader investment narrative.

Find 46 companies with promising cash flow potential yet trading below their fair value.

Wave Life Sciences Investment Narrative Recap

To own Wave Life Sciences, you need to believe its RNA editing platform can turn early clinical signals into approved drugs before cash pressure and competition bite. The updated RestorAATion-2 data for WVE-006 strengthen the case that AATD is still the key near term value driver, and they may become central to any accelerated approval discussion, but they do not remove the binary risk around future late stage trials or the company’s ongoing losses.

The most relevant recent announcement here is Wave’s February 2026 update that it had regained full rights to WVE-006 from GSK while keeping access to up to US$2.8 billion in potential milestones. This move concentrates both the upside from the AATD program and the execution risk squarely on Wave at the same time as RestorAATion-2 is producing more mature data, linking this asset even more tightly to future funding options and shareholder returns.

Yet behind the encouraging AATD data, investors should still pay close attention to how Wave’s widening net losses and reliance on future milestones could...

Wave Life Sciences’ narrative projects $138.5 million revenue and $26.1 million earnings by 2029. This requires 24.5% yearly revenue growth and a $209.7 million earnings increase from -$183.6 million today.

Uncover how Wave Life Sciences' forecasts yield a $22.19 fair value, a 237% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts saw revenue shrinking about 25% a year and still expected losses, so even with these new WVE-006 results, you should recognize how sharply opinions differ and consider how fresh data might shift both that pessimism and your own view of the company’s funding risk.

Explore 3 other fair value estimates on Wave Life Sciences - why the stock might be a potential multi-bagger!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Wave Life Sciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Wave Life Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Wave Life Sciences' overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 12 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.